Company profile
Aptevo Therapeutics Inc.
NASDAQ: APVO · Healthcare · Biotechnology
#744 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
35DFH 29DQ 49GM 22SS 45
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.0M
Employees
33
as of 2026-08-22
Market cap
$5.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.1M$3.1M2022
Net income-$26.0M-$26.0M2025
Operating income-$26.3M-$26.3M2025
Total assets$27.2M$27.2M2025
Liabilities$9.8M$9.8M2025
Equity$17.4M$17.4M2025
Revenue trend
FY2016 – FY2022 · USD
FY16
FY16
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2019
By product
Product100%
By geography
Not disclosed.
The read
What is Aptevo Therapeutics Inc.’s revenue?
Aptevo Therapeutics Inc. booked $3.1M in FY2022 revenue, contracting 75% year over year — slower than 87% of Healthcare companies we track, at a -833.9% net margin.
Peers · Healthcare
ADM Tronics Unlimited, Inc.——American Medical Technologies Inc.——TransCanna Holdings Inc.——Avitar, Inc.——Aridis Pharmaceuticals, Inc.——Dyadic International, Inc.39DNeighbors
King →Key facts
CEOJeffrey G. Lamothe
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeNASDAQ: APVO
Employees33
IPO date2016-07-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.